The firm is advancing its AI-driven multi-modal digital pathology platform as a tool for guiding clinical trial design and patient identification.

Imagene AI was founded in 2020 by CEO Dean Bitan, CDSO Jonathan Zalach and CTO Shahar Porat. The company uses a variety of ...

Imagene AI delivers a living intelligence engine for adaptive, insight-driven precision medicine. MIAMI, FL / ACCESS Newswire ...

Methods: IMAGENE is an open-label phase II basket study evaluating the efficacy and safety of niraparib and PD-1 inhibitor in patients with HRR gene-mutated cancers that have shown resistance to one ...

Background: This study evaluated the efficacy and safety of neoadjuvant Serplulimab combined with concurrent chemoradiotherapy for locally advanced resectable esophagogastric junction (EGJ) ...

Company Profile Imagene is a pioneering company in AI-powered precision oncology, utilizing AI to capture complex features and patterns within biopsy images and omics data modalities, transforming ...

WARREN, Ohio (MyValleyTributes) – Donald Lee Sprague, known affectionately as Don to his friends and family, passed away peacefully on Tuesday, May 13, 2025, at the age of 72, in Warren, Ohio ...

PHOENIX, ARIZONA / ACCESS Newswire / March 27, 2025 / The Accreditation Committee of the College of American Pathologists (CAP) has recently awarded accreditation to Imagene Laboratory, Phoenix ...

NEW YORK – Cancer diagnostics firm Imagene on Wednesday announced that it is collaborating with Tempus AI to launch an AI-based biomarker prediction panel for non-small cell lung cancer. Imagene's ...

Imagene's innovative lung assay, the first AI-based multi-gene panel for predicting key non-small cell lung cancer (NSCLC) biomarkers directly from biopsy images within minutes, combined with ...